Cargando…

Terlipressin effect on hepatorenal syndrome: Updated meta‐analysis of randomized controlled trials

BACKGROUND AND AIM: Hepatorenal syndrome (HRS) is a fatal complication of liver cirrhosis with a limited pharmacological option. Terlipressin is a vasoconstrictor that is approved in many countries but not yet in the United States. This is a meta‐analysis of randomized controlled trials (RCTs) to re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohamed, Mohamed M G, Rauf, Abdul, Adam, Abubakr, Kheiri, Babikir, Lacasse, Alexandre, El‐Halawany, Hani
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Publishing Asia Pty Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8341180/ https://www.ncbi.nlm.nih.gov/pubmed/34386597 http://dx.doi.org/10.1002/jgh3.12600

Ejemplares similares

Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis
por: Wang, Haiqing, et al.
Publicado: (2018)

Hepatorenal syndrome:Response to terlipressin and albumin and its determinants
por: Sarwar, Shahid, et al.
Publicado: (2016)

Good Enough? Terlipressin, Hepatorenal Syndrome, and the Usage of RRT
por: Belcher, Justin M.
Publicado: (2023)

An investigation of reconstituted terlipressin infusion stability for use in hepatorenal syndrome
por: Bui, Thi Ngoc Nhieu, et al.
Publicado: (2020)

The Effect of Terlipressin on Renal Replacement Therapy in Patients with Hepatorenal Syndrome
por: Velez, Juan Carlos Q., et al.
Publicado: (2023)

The Current Management of Hepatorenal Syndrome–Acute Kidney Injury in the United States and the Potential of Terlipressin
por: Flamm, Steven L., et al.
Publicado: (2021)

Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: A meta-analysis
por: Hiremath, Sharanabasayyaswamy B., et al.
Publicado: (2013)

Terlipressin versus Norepinephrine in the Treatment of Hepatorenal Syndrome: A Systematic Review and Meta-Analysis
por: Nassar Junior, Antonio Paulo, et al.
Publicado: (2014)

Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome
por: Kim, Hae Rim, et al.
Publicado: (2013)

Terlipressin-Induced Peripheral Cyanosis in a Patient with Liver Cirrhosis and Hepatorenal Syndrome
por: Chiang, Chi-Wen, et al.
Publicado: (2019)

Terlipressin for the Prevention and Treatment of Renal Decline in Hepatorenal Syndrome: A Drug Profile
por: Ayyad, Ahlam, et al.
Publicado: (2023)

Terlipressin and albumin for type 1 hepatorenal syndrome: does bacterial infection affect the response?
por: Altun, Reskan, et al.
Publicado: (2015)

Real‐world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome
por: Moore, Kevin, et al.
Publicado: (2020)

Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function
por: Huang, Xingyue, et al.
Publicado: (2023)

Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial
por: Karvellas, Constantine J., et al.
Publicado: (2023)

Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence
por: Bai, Zhaohui, et al.
Publicado: (2020)

Early treatment with terlipressin in patients with hepatorenal syndrome yields improved clinical outcomes in North American studies
por: Curry, Michael P., et al.
Publicado: (2023)

Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute‐on‐chronic liver failure
por: Wong, Florence, et al.
Publicado: (2022)

Terlipressin-Induced Skin Necrosis While Managing Hepatorenal Syndrome: A Rare Case Report From North India
por: Sudan, Sourav, et al.
Publicado: (2023)

Endothelin-1/Nitric Oxide Ratio as a Predictive Factor of Response to Therapy With Terlipressin and Albumin in Patients With Type-1 Hepatorenal Syndrome
por: Abdel-Razik, Ahmed, et al.
Publicado: (2020)

A Systematic Review of the Emerging Treatment for Hepatorenal Syndrome With a Principal Focus on Terlipressin: A Recent FDA-Approved Drug
por: Thangaraj, Santhosh Raja, et al.
Publicado: (2023)

Hepatorenal syndrome: Update on diagnosis and therapy
por: Acevedo, Juan G, et al.
Publicado: (2017)

Meta-analysis of Unguided Deescalation of Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Mohamed, Mohamed M. G., et al.
Publicado: (2022)

Safety and efficacy of terlipressin in acute-on-chronic liver failure with hepatorenal syndrome-acute kidney injury (HRS-AKI): a prospective cohort study
por: Kulkarni, Anand V., et al.
Publicado: (2022)

Patent foramen ovale closure versus medical therapy after cryptogenic stroke: An updated meta-analysis of all randomized clinical trials
por: Kheiri, Babikir, et al.
Publicado: (2019)

Terlipressin‐induced foot ischemia
por: Ata, Fateen, et al.
Publicado: (2020)

Hepatorenal Syndrome
por: Kiser, Tyree H.
Publicado: (2014)

Management of hepatorenal syndrome in liver cirrhosis: a recent update
por: Bera, Chinmay, et al.
Publicado: (2022)

Terlipressin or Europressin?
por: Leone, Marc
Publicado: (2009)

Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT‐0401 and REVERSE randomised clinical studies
por: Sanyal, A. J., et al.
Publicado: (2017)

Fractional excretion of sodium in hepatorenal syndrome: Clinical and pathological correlation
por: Alsaad, Ali A, et al.
Publicado: (2016)

Terlipressin for septic shock patients: a meta-analysis of randomized controlled study
por: Zhu, Yibing, et al.
Publicado: (2019)

Terlipressin-induced hyponatraemia
por: Gray, R, et al.
Publicado: (2014)

Best duration of dual antiplatelet therapy after drug-eluting stent implantation: an updated network meta-analysis of randomized controlled trials
por: Barbarawi, Mahmoud, et al.
Publicado: (2019)

Liver Kidney Crosstalk: Hepatorenal Syndrome
por: Nassar, Mahmoud, et al.
Publicado: (2021)

Metabolic syndrome and the hepatorenal reflex
por: Wider, Michael D.
Publicado: (2016)

Metabolic syndrome and the hepatorenal reflex
por: Wider, Michael D.
Publicado: (2016)

A Review of Hepatorenal Syndrome
por: Subedi, Abinash, et al.
Publicado: (2021)

COVID-19 and hepatorenal syndrome
por: Wu, Henry H L, et al.
Publicado: (2022)

Pharmacological treatment of hepatorenal syndrome: a network meta-analysis
por: Wang, Li, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0e880ktralkkch05tefs7mb5vb